Clinical Trial Update: Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on CTL019 (tisagenlecleucel) for pediatric B-cell acute lymphoblastic leukemia, including relapsed/refractory cases, with results completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CTL019 (tisagenlecleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-11-23